Total raised
$4.4M
Last: Series A 2018-07
Stage
Series A
Founded
2016
Headcount
3
HQ
Jerusalem
Sector
Health Tech & Life Sciences
About
TPCera develops a new type of immunomodulatory compound that shifts the immune system from an inflammatory state into an anti-inflammatory one. The company is focused on shifting macrophages from M1 to M2, which has the potential to modulate autoimmune diseases. TPCera's lead compound is TPC1022. Its subcutaneous and oral administrations have produced promising results in preclinical studies on three autoimmune mice models: lupus, colitis, and rheumatoid arthritis.
Funding history · 1 round · $4.4M total
2018-07
Series A
$3.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsimmunologycrohn-s-diseasebiopharmaceuticalpharma-companiesdrug-discoveryautoimmune-diseases